Features
Excel add-in
New
PowerPoint add-in
New
Pricing
FAQ
Sign in
Sign up
Sign up
Low
Medium
High
Download PNG
Download SVG
Revenue → Gross Profit: $9.1B
Gross Profit → Operating cost: $7.7B
Cardiometabolic health → Revenue: $7.4B
Mounjaro → Cardiometabolic health: $3.1B
Operating cost → Acquired IPR&D: $2.8B
Operating cost → R&D: $2.7B
Oncology → Revenue: $2.2B
Revenue → Cost of Revenue: $2.2B
Operating cost → Marketing, S&A: $2.1B
Gross Profit → Operating profit: $1.5B
Verzenio → Oncology: $1.4B
Trulicity → Cardiometabolic health: $1.3B
Zepbound → Cardiometabolic health: $1.3B
Immunology → Revenue: $1.2B
Operating profit → Net Profit: $0.9B
Taltz → Immunology: $0.9B
Jardiance → Cardiometabolic health: $0.7B
Operating profit → Taxes: $0.6B
Humalog → Cardiometabolic health: $0.5B
Neuroscience → Revenue: $0.4B
Other oncology → Oncology: $0.3B
Other → Revenue: $0.3B
Olumiant → Immunology: $0.3B
Cyramza → Oncology: $0.2B
Humulin → Cardiometabolic health: $0.2B
Emgality → Neuroscience: $0.2B
Basaglar → Cardiometabolic health: $0.2B
Erbitux → Oncology: $0.2B
Tyvyt → Oncology: $0.2B
Other diabetes → Cardiometabolic health: $0.1B
Forteo → Other: $0.1B
Other neuroscience → Neuroscience: $0.1B
Cialis → Other: $0.1B
Operating cost → Restructuring & other: $0.1B
Other income → Net Profit: $0.1B
Other immunology → Immunology: $0.1B
Others → Other: $0.1B
Zyprexa → Neuroscience: $0.0B
Baqsimi → Cardiometabolic health: $0.0B
Acquired IPR&D
$2.8B
-5% Y/Y
Baqsimi
$0.0B
Basaglar
$0.2B
Cardiometabolic health
$7.4B
57% Y/Y
Cialis
$0.1B
Cost of Revenue
$2.2B
17% Y/Y
Cyramza
$0.2B
Emgality
$0.2B
Erbitux
$0.2B
Forteo
$0.1B
Gross Profit
$9.3B
1% Y/Y
Humalog
$0.5B
Humulin
$0.2B
Immunology
$1.2B
20% Y/Y
Jardiance
$0.7B
Marketing, S&A
$2.1B
16% Y/Y
Mounjaro
$3.1B
Net Profit
$1.0B
Neuroscience
$0.4B
-80% Y/Y
Olumiant
$0.3B
Oncology
$2.2B
28% Y/Y
Operating cost
$7.7B
2% Y/Y
Operating profit
$1.5B
215% Y/Y
Other
$0.3B
-5% Y/Y
Other diabetes
$0.1B
Other immunology
$0.1B
Other income
$0.1B
Other neuroscience
$0.1B
Other oncology
$0.3B
Others
$0.1B
R&D
$2.7B
13% Y/Y
Restructuring & other
$0.1B
-81% Y/Y
Revenue
$11.4B
4% Y/Y
Taltz
$0.9B
Taxes
$0.6B
28% Y/Y
Trulicity
$1.3B
Tyvyt
$0.2B
Verzenio
$1.4B
Zepbound
$1.3B
Zyprexa
$0.0B
Eli Lilly Q3 FY24 Income Statement
created with SankeyArt.com
2024
Q1
Q2
Q3
Copy and edit diagram